Phase 1 study of CS-7017 in combination with FOLFIRI
Ontology highlight
ABSTRACT: Intervention name : CS-7017
INN of the intervention : efatutazone
Dosage And administration of the intervention : CS-7017(0.25-0.50 mg) administered orally twice a day
Control intervention name : null
Primary outcome(s): Safety and Pharmacokinetics
-To evaluate the safety profile according to CTCAE
-To evaluate the pharmacokinetics according to the protocol
Study Design: Open Label Phase 1 Study
DISEASE(S): Metastatic Crc Who Failed First-line Therapy
PROVIDER: 2610363 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA